Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Parameters of anxiety in children with cancer vary according to instrument used

06 Feb 2019

The severity, patterns over time and predictors of anxiety in children and adolescents undergoing chemotherapy or haematopoietic stem cell transplantation (HSCT) change with different instruments used, a new study has found.

Seventy-seven paediatric patients (median age 13.2 years; 35.1 percent female) participated, in whom self-reported anxiety at chemotherapy or HSCT initiation was measured using three instruments: the Paediatric Quality of Life Inventory (PedsQL) 3.0 Acute Cancer Module, the Paediatric Patient-Reported Outcomes Measurement Information System (PROMIS) Paediatric Short-Form (SF) and the Multidimensional Anxiety Scale for Children (MASC).

At baseline, the percentage of participants who had severe anxiety ranged from 13.0–28.6 percent and varied according to the instrument used. When the PedsQL (procedural anxiety subscale: p=0.037) and PROMIS (p=0.013) instruments were used, significant improvements in anxiety were observed. No such change was recorded by the MASC.

There also seemed to be a variation among instruments regarding predictive factors. Univariate linear regression analysis showed that in the PedsQL instrument, age was a significant risk factor for anxiety, such that children aged 16–18 years reported more worries than those aged 8–11 years (p=0.036).

In comparison, the MASC instrument reported that lower annual household income was also a significant risk factor for anxiety in the participants (p=0.028).

The present findings highlight the heterogeneous nature of childhood anxiety and the need for careful consideration when choosing a measurement instrument, said researchers. Future studies about anxiety in paediatric cancer should focus on a particular facet of anxiety.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.